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The peroxisome proliferator-activated receptor-γ (PPAR-γ) is a prototypical metabolic nuclear receptor that
acts as a lipid sensor, integrating the homeostatic control of energy, lipid, and glucose metabolism.This
perspective will highlight three lines of evidence which place PPAR-γ as a key player in a feed-forward pathway
favoring differentiation and energy storage by adipocytes.
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PPAR-γ: a thrifty transcription factor
co-ordinating adipogenesis and glucose
homeostasis
The peroxisome proliferator-activated receptor-γ (PPAR-γ)
is a prototypical metabolic nuclear receptor that acts as
a lipid sensor, integrating the homeostatic control of
energy, lipid, and glucose metabolism. PPAR-γ activity
is governed by binding of small lipophilic ligands, mainly
fatty acids, derived from nutrition or metabolic pathways
that are often controlled by PPAR-γ.The actions of
PPAR-γ are mediated by two protein isoforms, the widely
expressed PPAR-γ1 and adipose tissue-restricted
PPAR-γ2, produced by alternative splicing and differing
only by 28 additional NH2-terminal residues in PPAR-γ2.
Three main lines of evidence establish that PPAR-γ is
the centerpiece of a feed-forward pathway that favors
differentiation and energy storage by adipocytes and
coordinates the “thrifty response”. [Auwerx, 1999; Chawla
et al., 2001; Francis et al., 2003; Lee and Evans, 2002;
Michalik and Wahli, 1999; Picard and Auwerx, 2002;
Rosen and Spiegelman, 2001; Rosen et al., 2000; Sporn
et al., 2001].
Molecular and cellular studies
The initial suggestion that PPAR-γ stimulated
adipogenesis was based on the observation that
expression of PPAR-γ in cells was by itself sufficient to
induce adipocyte differentiation. Conversely, targeted
mutagenesis of the PPAR-γ gene in ES cells and knocking
down the endogenous PPAR-γ2 in cell lines confirmed
the commanding role of PPAR-γ in adipocyte
differentiation. Consistent with this, PPAR-γ increases
genes that promote fatty acid storage, whereas it
represses genes that induce lipolysis and fatty acid
release from adipocytes.
Mouse and human genetic studies
The lipodystrophy in the rare homozygous PPAR-γ
-/-
mice, together with the characterization of mice chimeric
for PPAR-γ
 -/- ES cells, has unequivocally demonstrated
the importance of PPAR-γ in adipose tissue development
in vivo. Interestingly, PPAR-γ
+/- mice are resistant to
obesity and are more insulin sensitive. Further support
for an important role of PPAR-γ in adipogenesis has come
from human genetic studies, which have linked the
PPARG locus on 3p25-p24 with obesity in Pima Indians.
Furthermore, the partial loss-of-function Pro12Ala
mutation in the PPAR-γ2-specific B exon lowers body
mass, and improves insulin sensitivity and lipid profile.
The association between the hypomorphic Ala substitution
and insulin sensitivity disappears when the data are
corrected for body mass, suggesting a primary effect on
fat mass. In contrast to this hypomorphic allele, the rare
Pro115Gln substitution constitutively activates PPAR-γ
by blocking the Ser114 PPAR-γ MAP kinase
phosphorylation site. In keeping with PPAR-γ′s adipogenic
role, carriers of the Pro115Gln gain-of function mutation
are obese and insulin resistant.The data on the Pro12Ala
and Pro115Gln mutations were, however, somewhat in
contrast with two dominant negative mutations, i.e.
Pro467Leu and Val290Met, that have been associated
with partial lipodystrophy, but also with severe insulin
resistance, diabetes and hypertension (Figure 1).
Pharmacological studies
PPAR-γ agonists, such as the thiazolidinediones,
invariably increase white adipose tissue (WAT) mass,
redistribute WAT from visceral to subcutaneous depots,
and induce the appearance of small, newly differentiated
adipocytes at the expense of large, mature adipocytes.
Whereas enhanced PPAR-γ activity is associated with
an increase in WAT, suboptimal PPAR-γ activation or
PPAR-γ antagonism is neutral or even reverses weight
gain. Partial PPAR-γ agonists or modulators, such as
FMOC-L-leucine, NC-2100 or MCC-555, are less
adipogenic but lower glucose more effectively then full
PPAR-γ agonists in vivo.This effect is, at least for some
of these partial agonists, linked to the recruitment of a
distinct set of coactivators to PPAR-γ. Furthermore,
inhibition of PPAR-γ /RXR activity by antagonists also
translates into improved insulin sensitivity in vivo.These
pharmacological studies are fully consistent with the
effects of the partial loss of PPAR-γ function in both
PPAR-γ +/- mice and carriers of the Pro12Ala PPAR-γ
substitution (Figure 1).
The evidence reviewed above underscores the
importance of PPAR-γ in adipogenesis, but fails to provide
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WAT is required for proper glucose homeostasis, since
lipodystrophy leads to severe insulin resistance.The
observation that PPAR-γ agonists increase fat mass along
with improving glucose control supports the notion that
WAT mediates some of their effects on glucose
homeostasis. A reduction in circulating free fatty acids,
by repartitioning them towards fat rather than muscle, is
an early consequence of PPAR-γ activation, and precedes
the decrease in glucose and triglyceride levels. Besides
fatty acids, WAT produces several adipokines, which
affect insulin signaling in other tissues, and whose
expression is also altered by PPAR-γ activation. Examples
are TNF-α, leptin, and resistin, secreted proportionally
with WAT mass, and adiponectin, whose levels are
inversely related to the amount of WAT.
The role of PPAR-γ in the control of glucose homeostasis
likely extends beyond its primary effects in WAT, and
effects of thiazolidinediones have been reported in
muscle, pancreatic β cells, and liver.These data are,
however, potentially compromised by the specificity of
the ligand.The importance of PPAR-γ in other tissues
was, however, recently underscored by decreased hepatic
trigylcerides levels and aggravated systemic insulin
resistance in mice with a liver-specific knockout of
PPAR-γ.
PPAR-γ from inflammation to
atherosclerosis
In addition to these thrifty activities in WAT, other PPAR-γ
activities, such as its role the differentiation of
macrophages, crucial components of the innate immune
system, might also be evolutionary beneficial. PPAR-γ
induced in monocytes following exposure to oxidized
LDLs (oxLDLs) activates the expression of the CD36
scavenger receptor, which increases oxLDL uptake and
provides the cells with natural PPAR-γ agonists. Such a
feed-forward cycle would predict that PPAR-γ is
predominantly pro-atherogenic, were it not effectively
counterbalanced by PPAR-γ -mediated reduction of
inflammatory cytokine production by macrophages, which
is clearly anti-atherogenic. Moreover, the expression of
ABCA1, a transporter involved in apoA1-mediated
cholesterol efflux from macrophages, is tightly regulated
by the cellular content of cholesterol, through
oxysterol-dependent activation of another nuclear
receptor, the liver X receptor (LXR). PPAR-γ has been
shown to activate ABCA1 expression indirectly via
enhanced transcription of LXR.The efficacy of PPAR-γ
agonists to reduce atherosclerosis is hence most likely
a consequence of both anti-inflammatory and indirect
LXR-mediated effects.The current epidemiological
increase in atherosclerosis could be considered as a
PPAR-γ -driven maladapted response in the
macrophages, which occurs when the inherent beneficial
effects (stimulation of the innate immune response and
cholesterol efflux) are overwhelmed by the
pro-atherogenic effects (increased OxLDL uptake). Such
conditions are potentially met by the chronic overload of
lipids characteristic of current affluent lifestyles in the
Western Hemisphere.
Figure 1.  Hypothesis summarizing the relationship between PPAR-γ
activity, adipogenesis and glucose homeostasis. This scheme is
based on both genetic (Pro115Gln, Pro12Ala, Pro467 Leu) and
pharmacological evidence (agonists, modulators or partial agonists, and
antagonists). Only human mutations are shown for simplicity, but studies
in mouse mutants support the human data. Higher PPAR-γ activity
translates into insulin sensitization, but is associated with increased fat
mass accretion.This underscores the importance of PPAR-γ modulation
- or even antagonism - as the preferred strategy to combat the metabolic
syndrome.
PPAR-γ, caloric restriction, fat and aging
From an evolutionary perspective, a “thrifty response”,
clearly favors survival. In apparent contradiction, caloric
restriction, referring to a dietary regimen low in calories
without undernutrition, is also known to extend lifespan
in organisms, ranging from yeast to non-human primates.
The beneficial effects of caloric restriction have also been
associated with alterations in metabolism, more particular
the insulin/insulin-like growth factor 1 (IGF-1) pathways
and a decreased fat mass.These pathways converge on
transcription factors of the forkhead family (Daf16 in the
worm and FOXO1-3 in mammals), which are activated
when insulin/IGF-1 signaling decreases, translating
ultimately into the increased stress resistance, the
hallmark of caloric restriction.The most plausible
hypothesis explaining the anti-aging effects of caloric
restriction is that a reduced flow of carbon through the
glycolytic pathways will slow down the rate of conversion
of NAD to NADH.The altered NAD/NADH ratio will then
be recognized by neuro-endocrine sensors that reduce
the production of growth hormone by the pituitary (and
in turn also IGF-1) and insulin by the pancreas.The
importance of insulin/IGF-1/FOXO signaling in longevity
is supported by the extended lifespan of humans, mice,
C. elegans, and Drosophila with mutations in this signaling
cascade. It is at present unclear how PPAR-γ interfaces
with this signaling pathway, but the fact that PPAR-γ
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Perspective PPAR-γ: a thrifty transcription factorFigure 2.  Physiological effects of PPAR-γ activation. PPAR-γ induces adipocyte differentiation and genes involved in fat deposition. Plasma-derived
fatty acids are directed to adipose tissue at the expense of skeletal muscle, which increases glucose uptake and utilization in the muscle. Direct effects
of PPAR-γ activation have also been observed in liver, including decreased gluconeogenesis and increased fat uptake and storage. Additionally, PPAR-γ
activation results in increased cholesterol efflux in macrophages via upregulation of ABCA1, but also increased uptake of proatherogenic oxidized LDL
particles via upregulation of CD36.
coordinates adipogenesis and glucose homeostasis, leads
us to speculate that it also may affect longevity.
Too much of a good thing …. harms
All this suggests that moderate (or partial) levels of
PPAR-γ activation coordinate an evolutionary beneficial
and adaptive response (Figure 2). Longevity is improved
because efficient energy conservation and storage allows
survival of episodes of food shortage, and an enhanced
innate immune response helps to combat infections and
uncontrolled cell proliferation. Our current affluent life
style, which exposes us to excessive levels of natural
PPAR-γ activators, brings this tightly regulated system
out of balance. Being born with a silver spoon in our
mouth now turns this once favorable response into a
detrimental one, which contributes to the pathogenesis
of life-style associated diseases, such as obesity, type 2
diabetes, and atherosclerosis.This also indicates that
modulating (or inhibiting) PPAR-γ activity, rather than
activating, might be the preferred therapeutic strategy to
treat the above disorders.
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